A Widely Inclusive, Hybrid-Decentralized Pilot Trial Utilizing β-hydroxy-β-methylbutyrate to Lower IGFBP7 Levels in People With ALS

NCT07589764 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Amyotrophic Lateral Sclerosis ALS

Interventions

DRUG: β-hydroxy-β-methylbutyrate (HMB)

Sponsor

Duke University

Collaborators

[object Object]